o_19ntugujs11ikbdrctt1teabbla.pdf
MRRSE.Com announces addition of new report"Ovarian Cancer Therapeutics Market the World Cancer Research Market-Analysis, Size, Share, Growth, Trends and Forecast2015-2020"to its database
MRRSE.Com announces addition of new report"Ovarian Cancer Therapeutics Market the World Cancer Research Market-Analysis, Size, Share, Growth, Trends and Forecast2015-2020"to its database
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Ovarian Cancer Therapeutics in Asia-Pacific Markets to 2020 - Analysis, Size,<br />
Share, Growth, Trends and Forecast<br />
Though ovarian cancer ranks seventh in the list of the most common types of cancers<br />
worldwide, its affliction rate continues to rise.<br />
These are the estimates of the World Cancer Research Fund International, which also states<br />
that the prevalence of this disease remarkably higher in less developed countries.<br />
The Asia Pacific market has not only seen a rise in the number of ovarian cancer cases<br />
reported annually, but has also been a fertile playground for several new therapies to be<br />
developed.<br />
Browse the full Asia Pacific Ovarian Cancer Market Report : http://www.mrrse.com/ovariancancer-therapeutics<br />
Within Asia Pacific, countries where ovarian cancer pipelines are most active are: China, India,<br />
Japan and Australia. Even as this market continues to thrive and grow at a steady pace, a<br />
recent market report by MRRSE carries some interesting trends. These are:<br />
· The Asia Pacific ovarian cancer therapies market features a white space for maintenance<br />
therapies. At present, the most widely used type of chemotherapy is the platinum-based one.<br />
The use of paclitaxel and carboplatin chemotherapy regimen is seen to be the most<br />
commonly-used one. Data shows that this is the most widely used standard of care for<br />
treating platinum-sensitive ovarian cancer in both first-line as well as recurrent cases.<br />
As the efficacy of the initial treatment is seen to be satisfactory, the remission rates continue<br />
to remain above acceptable levels. However, studies also show that nearly all patients with<br />
relapse (after they have been through remission and relapse) either succumb to ovarian<br />
cancer or develop platinum-resistant ovarian cancer.
· The prognosis for platinum-resistant ovarian cancer is currently poor, and leaves a wide gap<br />
where companies can fill with innovative solutions.<br />
Thus, the demand for maintenance therapies is high in the Asia Pacific ovarian cancer market.<br />
Moreover, the time is right for<br />
market players to invest in developing more effective treatment solutions for patients that are<br />
afflicted with platinum-sensitive ovarian cancer.<br />
· Approvals for olaparib and trebananib, two promising drug candidates for the treatment of<br />
ovarian cancer, are expected to come through before 2020.<br />
But even after being approved, their penetration rates will remain somewhat restricted to the<br />
surface of the ovarian cancer market. Currently, the ovarian cancer therapeutics pipeline is<br />
rather crowded, but it still leaves a lot to be desired on the efficacy of late-stage drugs. Only<br />
minimal improvements have been observed in progression-free survival rates.<br />
Browse the full Press Release of Ovarian Cancer Market : http://www.mrrse.com/ovariancancer-therapeutics-market-report<br />
Based on the factors discussed above, it can be said that the ovarian cancer market in Asia<br />
Pacific will not be driven by new drug approvals.<br />
Growth will primarily be a result of inflation and the general rise in the prevalence rates of<br />
ovarian cancer. On the positive side, the large number of drug candidates in the ovarian<br />
cancer pipeline will keep the industry’s interest levels and degree of competition moderately<br />
high.<br />
Send An Enquiry: http://www.mrrse.com/enquiry/112<br />
Table of Contents:<br />
1.1 List of Tables<br />
1.2 List of Figures
2 Introduction<br />
2.1 Disease Pathophysiology<br />
2.1.1 Ovarian Cancer – A Group of Distinct Diseases<br />
2.1.2 Ovarian Cancer is Highly Heterogenic with Multiple Mutations and Affected Signaling<br />
Pathways<br />
2.2 Symptoms and Diagnosis<br />
2.3 Risk Factors<br />
2.3.1 Age<br />
2.3.2 Inherited Genetic Mutations<br />
2.3.3 Greater Number of Lifetime Ovulations<br />
2.3.4 Weight<br />
2.3.5 Previous Medical Conditions<br />
2.4 Treatment Algorithm<br />
2.4.1 Surgery<br />
2.4.2 First-Line Chemotherapy<br />
2.4.3 Maintenance Therapy<br />
2.5 Recurrent Disease<br />
3 Marketed Products<br />
3.1 Carboplatin<br />
3.2 Paclitaxel<br />
3.3 Gemcitabine<br />
3.4 Topotecan
3.5 Pegylated Liposomal Doxorubicin<br />
3.6 Yondelis<br />
3.7 Avastin<br />
4 Product Pipeline<br />
4.1 Overview of Pipeline by Phase and Route of Administration<br />
4.2 Overview of Pipeline by Molecule Type, Mechanism of Action and Molecular Target<br />
4.2.1 Molecular Targets in the Developmental Pipeline<br />
4.3 Clinical Trials<br />
4.3.1 Clinical Trial Duration<br />
4.3.2 Clinical Trial Size<br />
4.3.3 Failure Rate<br />
4.3.4 Discussion<br />
4.4 Late-Stage Drugs in Developmental Pipeline<br />
4.4.1 Niraparib<br />
4.4.2 Olaparib<br />
4.4.3 Vargatef<br />
4.4.4 Trebananib<br />
4.4.5 Farletuzumab<br />
4.4.6 Karenitecin<br />
4.5 Discussion<br />
5 Market Forecasts<br />
5.1 Asia-Pacific<br />
5.1.1 Overview
5.1.2 Treatment Use Patterns and Revenues in Asia-Pacific Markets<br />
5.2 India<br />
5.2.1 Treatment Use Patterns<br />
5.2.2 Annual Cost of Therapy<br />
5.2.3 Market Forecast<br />
5.3 China<br />
5.3.1 Treatment Use Patterns<br />
5.3.2 Annual Cost of Therapy<br />
5.3.3 Market Forecast<br />
5.4 Japan<br />
5.4.1 Treatment Use Patterns<br />
5.4.2 Annual Cost of Therapy<br />
5.4.3 Market Forecast<br />
5.5 Australia<br />
5.5.1 Treatment Use Patterns<br />
5.5.2 Annual Cost of Therapy<br />
5.5.3 Market Forecast<br />
5.6 Drivers and Barriers<br />
5.6.1 Drivers<br />
5.6.2 Barriers<br />
6 Deals<br />
6.1 Licensing Deals<br />
6.1.1 Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338
6.1.2 PharmaMar Enters into Licensing Agreement with Janssen for Yondelis<br />
6.1.3 Hana Enters into Licensing Agreement with Tekmira<br />
6.1.4 AstraZeneca Enters into Licensing Agreement with Merck for MK-1775<br />
6.1.5 Tesaro Enters into Licensing Agreement with Merck Sharp & Dohme for Cancer Drug<br />
6.1.6 Oasmia Enters into Licensing Agreement with Medison for Paclical<br />
6.1.7 Orion Enters into Agreement with Oasmia<br />
6.1.8 Ohio University Enters into Licensing Agreement with Phosplatin<br />
6.1.9 Genta Enters into Licensing Agreement with Daiichi Sankyo<br />
6.1.10 Celldex Enters into Licensing Agreement with the Ludwig Institute for Cancer Research<br />
6.1.11 NanoCarrier Enters into Licensing Agreement with Kowa for NC-6300<br />
6.2 Co-development Deals<br />
6.2.1 Bristol-Myers Squibb Enters into Co-development Agreement with Ono Pharma<br />
6.2.2 Merck Enters into Co-development Agreement with Endocyte for Cancer Drug<br />
6.2.3 Pfizer Enters into Research Agreement with BC Cancer Agency and Vancouver Prostate<br />
Centre<br />
6.2.4 Almac Discovery Enters into an Agreement with Queen’s University Belfast for Drug<br />
Discovery<br />
7 Appendix<br />
7.1 All Pipeline Drugs by Phase<br />
7.1.1 Discovery<br />
7.1.2 Preclinical<br />
7.1.3 IND/CTA-Filed<br />
7.1.4 Phase I<br />
7.1.5 Phase II
7.1.6 Phase III<br />
7.1.7 Pre-Registration<br />
7.2 Market Forecasts to 2020<br />
7.2.1 Asia-Pacific<br />
7.2.2 India<br />
7.2.3 China<br />
7.2.4 Japan<br />
7.2.5 Australia<br />
7.3 Abbreviations<br />
7.4 Bibliography<br />
7.5 Research Methodology<br />
7.5.1 Coverage<br />
7.5.2 Secondary Research<br />
7.5.3 Primary Research<br />
7.5.4 Therapeutic Landscape<br />
7.5.5 Geographical Landscape<br />
7.5.6 Pipeline Analysis<br />
7.6 Expert Panel Validation<br />
7.7 Contact Us<br />
7.8 Disclaimer<br />
Latest Report:
Sulfur Chemicals Market - Global Industry Expert Opinions Analysis, Emerging<br />
Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast<br />
2015 – 2020<br />
http://www.mrrse.com/sulfur-chemicals-market<br />
Description:<br />
Sulfur is one the most important raw material of the chemical industry.<br />
Majority of sulfur is used in preparation of its derivatives such as sulfuric acid, sodium hydro<br />
sulfide, sodium hydrosulfite, sodium sulfite, sodium sulfide and sodium thiosulfate. Sodium<br />
sulfites include dry and liquid sodium sulfite, sodium bisulfate solution and sodium<br />
metabisulfite.<br />
These chemicals are majorly used in applications like paper, pulp and textile processing, food<br />
and photographic industries and in water treatment as reducing and precipitating agent.<br />
Hydrogen Cyanide Market - Global Industry Expert Opinions Analysis, Emerging<br />
Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast<br />
2015 – 2020<br />
http://www.mrrse.com/hydrogen-cyanide-market<br />
Hydrogen cyanide is also known as prussic acid. Hydrogen cyanide is an inorganic compound<br />
that is colorless in nature. Hydrogen cyanide is extremely poisonous liquid which boils at the<br />
slightly above room temperature.<br />
Hydrogen cyanide is weakly acidic and partially ionizes in the water solutions to form cyanide<br />
ions. Hydrogen cyanide has a faint, bitter, almond like smell that sometimes is undetected.<br />
Hydrogen cyanide is usually manufactured in large quantities at an industrial scale.<br />
Hydrogen cyanide is an essential and highly valuable precursor for the manufacturing of a<br />
range of chemical compounds from polymers to that of pharmaceuticals. Hydrogen cyanide is<br />
included among the chemical welfare (CW) list of chemicals that are known to be poisonous in<br />
nature.<br />
About Us:
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market<br />
intelligence reports.<br />
Headquartered in New York, U.S., MRRSE is driven by a stellar team of research experts and<br />
advisors trained to offer objective advice.<br />
Our sophisticated search algorithm returns results based on the report title, geographical<br />
region, publisher, or other keywords.<br />
MRRSE partners exclusively with leading global publishers to provide clients single-point<br />
access to top-of-the-line market research. MRRSE’s repository is updated every day to keep its<br />
clients ahead of the next new trend in market research, be it competitive intelligence, product<br />
or service trends or strategic consulting.<br />
Contact<br />
State Tower<br />
90, State Street<br />
Suite 700<br />
Albany, NY - 12207<br />
United States<br />
Telephone: +1-518-618-1030<br />
Email: sales@mrrse.com<br />
Website: http://www.mrrse.com/